Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris

Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris

In a 52-week trial, rituximab was found to be superior to mycophenolate mofetil in producing sustained remission of pemphigus vulgaris and in reducing glucocorticoid use. There were more serious adverse events with rituximab than with mycophenolate mofetil.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2021-06, Vol.384 (24), p.2295-2305
Hauptverfasser: Werth, Victoria P, Joly, Pascal, Mimouni, Daniel, Maverakis, Emanual, Caux, Frédéric, Lehane, Patricia, Gearhart, Liudmila, Kapre, Audrey, Pordeli, Pooneh, Chen, Diana M
Format: Artikel
Sprache:eng
Schlagworte:
Adverse events
Antibodies
Autoimmune diseases
Clinical trials
Disease control
Drug dosages
Glucocorticoids
Immunotherapy
Intravenous administration
Laboratories
Monoclonal antibodies
Mycophenolate mofetil
Mycophenolic acid
Patients
Pemphigus
Population
Quality of life
Questionnaires
Remission
Rituximab
Skin
Skin diseases
Statistical analysis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In a 52-week trial, rituximab was found to be superior to mycophenolate mofetil in producing sustained remission of pemphigus vulgaris and in reducing glucocorticoid use. There were more serious adverse events with rituximab than with mycophenolate mofetil.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2028564